Dytor-Plus-LS 15 Tablets

babies: not applicable. lactating mothers: it is safe during breastfeeding.
pregnancy: it is unsafe during pregnancy. limited studies have shown harmful effects on developing babies.
please consult your doctor. driving: spironolactone and torsemide tablet may decrease alertness, affects vision and may cause dizziness and sleep.
do not drive if these symptoms occur. alcohol: avoid consumption of alcohol while taking spironolactone and torsemide tablet.
kidney: spironolactone and torsemide tablets should be used with caution in patients with kidney disease. you may require dosage adjustment.
please consult your doctor. liver: spironolactone and torsemide tablet should be used with caution in patients with liver disease.
you may require dosage adjustment. please consult your doctor..

Dehydration Increased blood uric acid Breast enlargement in male Decreased magnesium, calcium & sodium level in blood.

DYTOR PLUS LS tablet is an aldosterone receptor antagonist, diuretics and hypertensive agents. It works by acting on different parts of your kidney to remove extra water and electrolytes while maintaining potassium balance in your body..

If you miss a dose, take it as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• DYTOR PLUS LS combination tablet which removes excess water from the body. • Take it in the morning with breakfast to avoid getting upset to urinate. • This tablet may decrease alertness, affects vision and may cause dizziness and sleep. Do not drive if these symptoms rise. • It may cause excessive urine production, dehydration and low electrolyte levels.
Inform your doctor if you experience dizziness, tiredness or muscle weakness. • Your doctor may advise regular monitoring of kidney function and electrolyte..

serious • torsemide + amikacin: concurrent use leads to an increase in the toxicity • torsemide + gentamicin: concurrent use leads to an increase in the toxicity • torsemide + ivosidenib: concurrent use leads to a decrease in the level or effect of torsemide by affecting hepatic enzyme cyp2c9/10 metabolism • torsemide + paromomycin: concurrent use leads to an increase in the toxicity • spironolactone + potassium acid phosphate: concurrent use leads to increase serum potassium • spironolactone + triamterene: concurrent use leads to increase serum potassium • spironolactone + drospirenone: concurrent use leads to increase serum potassium.